Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Asahi Intecc Co ( (JP:7747) ).
Asahi Intecc Co. reported consolidated net sales of 71,266 million yen for the first half of the fiscal year ending June 2026, a year-on-year increase of 15.9 percent, driven by solid performance in both its Medical and Device divisions. The Medical Division saw robust growth in cardiovascular products, notably PCI guidewires and penetration catheters across all regions, and in non-cardiovascular areas such as peripheral devices worldwide and abdominal products outside China.
The Device Division posted higher sales in both medical and industrial components, supported by the consolidation of Nitta Mold as a subsidiary and increased business in U.S. cardiovascular inspection catheter components. Industrial components also benefited from stronger overseas leisure-related demand, while a weaker yen added 1,065 million yen to sales, underscoring the company’s exposure to currency movements and its expanding international footprint.
The most recent analyst rating on (JP:7747) stock is a Hold with a Yen2759.00 price target. To see the full list of analyst forecasts on Asahi Intecc Co stock, see the JP:7747 Stock Forecast page.
More about Asahi Intecc Co
Asahi Intecc Co. is a Japanese manufacturer operating in the medical and industrial device sectors, with a strong focus on cardiovascular and non-cardiovascular medical products. The company also supplies medical and industrial components, including catheter and inspection-related parts, and serves global markets such as the U.S., China, and other overseas regions.
Average Trading Volume: 1,048,052
Technical Sentiment Signal: Buy
Current Market Cap: Yen691.8B
For detailed information about 7747 stock, go to TipRanks’ Stock Analysis page.